Drugs / Celestone Soluspan
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CELESTONE SOLUSPAN | — | 1965-03-03 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03445611 | Sep → Oct 2019 | osteoarthritis, knee | Loma Linda University | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03668860 Comparator | Sep 2018 → Feb 2019 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Celestone soluspan | “Material identification: Celestone soluspan or Kenalog 1% 50mL multiuse vials without epinephrine, 1% 5mL lidocaine vials, 10mL syringes with 21mm x 1 ¼ inch needles, alcohol...” NCT03445611 ↗ |
| Route | Intramuscular | “administered intramuscularly at gluteal or thigh region” NCT03668860 ↗ |